Baillie Gifford & Co. Has $129.04 Million Holdings in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)

Key Points

• Baillie Gifford & Co. reduced its stake in Recursion Pharmaceuticals by 1.9%, holding approximately 24.4 million shares after selling over 471,000 shares in the first quarter.
• Recursion Pharmaceuticals reported a quarterly loss of ($0.50) per share, missing analysts' estimates of ($0.44), with revenue of $14.75 million, below expectations of $18.12 million.
• Institutional investors own 89.06% of Recursion Pharmaceuticals, indicating strong institutional interest and involvement in the stock.

Baillie Gifford & Co. decreased its holdings in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX - Free Report) by 1.9% in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 24,393,015 shares of the company's stock after selling 471,043 shares during the period. Baillie Gifford & Co. owned about 6.07% of Recursion Pharmaceuticals worth $129,039,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors have also modified their holdings of the business. Man Group plc acquired a new stake in shares of Recursion Pharmaceuticals during the fourth quarter worth about $479,000. Rockefeller Capital Management L.P. increased its holdings in shares of Recursion Pharmaceuticals by 323.1% in the fourth quarter. Rockefeller Capital Management L.P. now owns 281,922 shares of the company's stock valued at $1,906,000 after purchasing an additional 215,283 shares during the period. Invesco Ltd. raised its stake in shares of Recursion Pharmaceuticals by 54.6% during the fourth quarter. Invesco Ltd. now owns 178,619 shares of the company's stock worth $1,207,000 after purchasing an additional 63,068 shares during the last quarter. Norges Bank purchased a new position in Recursion Pharmaceuticals in the 4th quarter valued at $23,429,000. Finally, California State Teachers Retirement System grew its position in Recursion Pharmaceuticals by 30.7% in the 4th quarter. California State Teachers Retirement System now owns 231,535 shares of the company's stock valued at $1,565,000 after buying an additional 54,449 shares during the last quarter. Institutional investors and hedge funds own 89.06% of the company's stock.

Recursion Pharmaceuticals Stock Performance

NASDAQ RXRX traded up $0.12 during trading hours on Wednesday, hitting $6.07. 7,894,939 shares of the stock were exchanged, compared to its average volume of 25,380,186. Recursion Pharmaceuticals, Inc. has a 12-month low of $3.79 and a 12-month high of $12.36. The company has a quick ratio of 4.11, a current ratio of 4.11 and a debt-to-equity ratio of 0.02. The company has a market cap of $2.47 billion, a price-to-earnings ratio of -3.42 and a beta of 0.91. The stock has a 50-day moving average of $5.18 and a 200 day moving average of $5.95.

Recursion Pharmaceuticals (NASDAQ:RXRX - Get Free Report) last announced its earnings results on Monday, May 5th. The company reported ($0.50) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.44) by ($0.06). Recursion Pharmaceuticals had a negative return on equity of 74.70% and a negative net margin of 961.32%. The firm had revenue of $14.75 million for the quarter, compared to analyst estimates of $18.12 million. During the same quarter last year, the business posted ($0.39) EPS. The firm's revenue was up 7.2% compared to the same quarter last year. As a group, equities research analysts forecast that Recursion Pharmaceuticals, Inc. will post -1.57 earnings per share for the current year.

Analyst Ratings Changes

A number of equities analysts recently weighed in on RXRX shares. Needham & Company LLC reiterated a "buy" rating and issued a $8.00 price objective on shares of Recursion Pharmaceuticals in a research report on Tuesday, July 8th. Morgan Stanley began coverage on shares of Recursion Pharmaceuticals in a research report on Thursday, July 3rd. They issued an "equal weight" rating and a $5.00 price objective on the stock. Four investment analysts have rated the stock with a hold rating and two have given a buy rating to the company. According to MarketBeat.com, Recursion Pharmaceuticals currently has a consensus rating of "Hold" and an average price target of $7.00.

Recursion Pharmaceuticals Company Profile

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.